• Are Prescription Drug Prices Changing – for the Better?

    The news this week is mixed on whether or not the Trump Administration’s push to lower the cost of prescription drugs is working. CVS is launching their own program to target expensive new drugs, while the US Health Secretary repeats the desire to eliminate drug rebates. Anthem is taking steps to make it easier for ...

  • The Costs of Prescription Drugs

    This week’s Innovation Partners BioBlog looks at costs - the cost of prescription drugs. From CVS shifting drug pricing leverage to new data showing hidden costs in Medicare’s prescription drug program, the cost of medication is definitely in the spotlight right now. CVS' move to lean on ICER data could mean dramatic shift in drug ...

  • Bundled Payments Reduce Referrals to SNFs, FDA Warning about the Use of Antibiotics after Donor Stem Cell Transplant, More

    This week's BioBlog looks at the world of pharmaceuticals and the changes, updates, and news that shape the industry. The FDA issued a warning on the use of azithromycin after donor stem cell transplant this week. Hospitals are reducing their referrals to skilled nursing facilities if they switch to a bundled payment system. Cigna's potential ...

  • Advances in the Fight Against Cancer, Drug Prices and More

    This week the FDA approved a new treatment for rare adrenal gland tumors. Researchers at Johns Hopkins made a discovery that could lead to breakthroughs in the fight against cancer, and drug companies are talking openly about drug prices. These top stories and more in this week’s Innovation Partners BioBlog. FDA approves Progenics' treatment for ...

  • Soaring Drug Prices Under Continuing Scrutiny

    Soaring drug prices continue to be under scrutiny this week as our lead story attests. CAR-T therapy offers hope to cancer patients but at what cost to insurers? The Trump Administration continues its offensive against big pharma and drug price increases. These top stories and more in this week’s Innovation Partners BioBlog. Staggering Prices Slow ...

  • Changes to Medicare, the High Cost of Drugs and New Cancer Research

    CMS proposes changes to Medicare coverage, a move which many criticize. The Trump administration continues it war on drug pricing, while new studies demonstrate the effectiveness by which cancer drugs reach specific cells. This and more in this week’s Innovation Partners BioBlog. Trump slams Pfizer after July 1 drug price hikes U.S. President Donald Trump ...

  • Amazon Launches Competitively Priced Drugstore Items, Kymriah Funding Is Cut and More

    This week’s Innovation Partners BioBlog surveys the pharmaceutical world for updates from many different quarters. E-commerce giant Amazon announced it would launch a line of competitively priced over the counter medications while Novartis’ Kyrmiah funding was cut by Medicare/Medicaid after questions arose about influence and payments. This and more in the BioBlog. Amazon undercuts drugstores ...

  • News from the Pharmaceutical Industry, Plus Changes to Medicaid in Effect

    This week’s Innovation Partners Bio Blog features news and updates from Array BioPharma, Merck, Puma, and other pharmaceutical companies in this week’s BioBlog as well as updates on 340B and the new, controversial Medicaid changes, the first such changes in 53 years. Array BioPharma Announces FDA Approval of BRAFTOVI™ (encorafenib) in Combination with MEKTOVI®(binimetinib) The ...

  • The Business of Healthcare – News

    The business of healthcare is the top of this week’s Innovation Partners BioBlog. AllianceRx Walgreens selects Inovalon for its new cloud-based specialty pharmacy, and there’s a move afoot to learn from retail giants like Amazon and apply the lessons to health organization management. Meanwhile, states plan to sue the Trump administration over its adjustments to ...

  • Rare Soft Tissue Tumor Genome Sequenced, Integrative Treatment for Breast Cancer Patients and More

    This week’s Innovation Partners BioBlog focuses on oncology updates. The genome for a rare soft tissue tumor affecting infants has been sequenced, opening the doors for potential treatments. The FDA listed two initiatives targeting generic cancer drugs, and ASCO endorsed integrative oncology guidelines for breast cancer patients. This and more in the BioBlog ASCO endorses ...